Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 327

1.

Oestrogen redux: will transdermal delivery rebalance the risk-benefit equation?

Schellhammer PF.

BJU Int. 2017 May;119(5):653-654. doi: 10.1111/bju.13737. No abstract available.

PMID:
28393497
2.

A Urologist's Personal View of Prostate Cancer.

Schellhammer PF.

Turk J Urol. 2016 Sep;42(3):121-6. doi: 10.5152/tud.2016.50318. Review.

3.

Legends in Urology.

Schellhammer PF.

Can J Urol. 2016 Jun;23(3):8261-4. No abstract available.

4.

Re: Should the Urologist Treat Castration Resistant Prostate Cancer? Yes/No.

Schellhammer PF.

J Urol. 2016 Mar;195(3):803; discussion 803-4. doi: 10.1016/j.juro.2015.08.106. Epub 2015 Nov 27. No abstract available.

PMID:
26638024
5.

The clinical and economic implications of specimen provenance complications in diagnostic prostate biopsies.

Wojno K, Hornberger J, Schellhammer P, Dai M, Morgan T.

J Urol. 2015 Apr;193(4):1170-7. doi: 10.1016/j.juro.2014.11.019. Epub 2014 Nov 14. Review.

PMID:
25463992
6.

Metastatic castrate-resistant prostate cancer.

Schellhammer P.

Urol Oncol. 2015 Jan;33(1):51-2. doi: 10.1016/j.urolonc.2014.07.006. Epub 2014 Sep 3. No abstract available.

PMID:
25192835
7.

Gonadal steroids and body composition, strength, and sexual function in men.

Schellhammer PF.

N Engl J Med. 2013 Dec 19;369(25):2456. doi: 10.1056/NEJMc1313169#SA3. No abstract available.

PMID:
24350957
8.

Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.

Culp SH, Schellhammer PF, Williams MB.

Eur Urol. 2014 Jun;65(6):1058-66. doi: 10.1016/j.eururo.2013.11.012. Epub 2013 Nov 20.

PMID:
24290503
9.

Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer.

Beer TM, Schellhammer PF, Corman JM, Glodé LM, Hall SJ, Whitmore JB, Frohlich MW, Penson DF.

Urology. 2013 Aug;82(2):410-5. doi: 10.1016/j.urology.2013.04.049.

PMID:
23896100
10.

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW.

Urology. 2013 Jun;81(6):1297-302. doi: 10.1016/j.urology.2013.01.061. Epub 2013 Apr 9.

PMID:
23582482
11.

Intermittent versus continuous androgen deprivation in prostate cancer.

Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr.

N Engl J Med. 2013 Apr 4;368(14):1314-25. doi: 10.1056/NEJMoa1212299.

12.

Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing.

Bjurlin MA, Carter HB, Schellhammer P, Cookson MS, Gomella LG, Troyer D, Wheeler TM, Schlossberg S, Penson DF, Taneja SS.

J Urol. 2013 Jun;189(6):2039-46. doi: 10.1016/j.juro.2013.02.072. Epub 2013 Feb 26. Review.

13.

Treater to target: a urologist's personal experience with prostate cancer.

Schellhammer PF.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):143-5. doi: 10.1093/jncimonographs/lgs027. No abstract available.

14.

Intermittent androgen suppression for rising PSA level after radiotherapy.

Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Hall E, Schellhammer PF, Ding K, Klotz L.

N Engl J Med. 2012 Sep 6;367(10):895-903. doi: 10.1056/NEJMoa1201546. Erratum in: N Engl J Med. 2012 Dec 6;367(23):2262.

15.

Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.

Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF.

J Natl Cancer Inst. 2012 Jul 18;104(14):1107-9; author reply 1109-12. doi: 10.1093/jnci/djs279. No abstract available.

PMID:
22825556
16.

Life after failure of traditional androgen deprivation therapy.

Schellhammer P.

Urol Oncol. 2012 Jul-Aug;30(4 Suppl):S10-4. doi: 10.1016/j.urolonc.2012.01.009. Review.

PMID:
22795075
17.

Re: Prediction of erectile function following treatment for prostate cancer.

Schellhammer P.

Eur Urol. 2012 Mar;61(3):622. doi: 10.1016/j.eururo.2011.12.037. No abstract available.

PMID:
22289975
18.

Treatment options for localized prostate cancer.

Mohan R, Schellhammer PF.

Am Fam Physician. 2011 Aug 15;84(4):413-20. Review.

19.

Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.

Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, Schellhammer PF, Jones LA, Xu Y, Kylstra JW, Frohlich MW.

Clin Cancer Res. 2011 Jul 1;17(13):4558-67. doi: 10.1158/1078-0432.CCR-10-3223. Epub 2011 May 10.

20.

Editorial comment.

Schellhammer PF.

J Urol. 2011 Mar;185(3):854; author reply 854. doi: 10.1016/j.juro.2010.10.091. Epub 2011 Jan 15. No abstract available.

PMID:
21239016

Supplemental Content

Loading ...
Support Center